FTY720 prevents progression of renal fibrosis by inhibiting renal microvasculature endothelial dysfunction in a rat model of chronic kidney disease

Journal of Molecular Histology

Volumn 44, Issue 6, 2013, Pages 693-703

  Ni, Haifeng ^a   Chen, Junfeng ^a   Pan, Mingming ^a   Zhang, Minghui ^a   Zhang, Jiandong ^a   Chen, Pingsheng ^b   Liu, Bicheng ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

Chronic kidney disease; Endothelial dysfunction; Endothelial nitric oxide synthase; Fibrosis; FTY720; Nitric oxide

Indexed keywords

CD31 ANTIGEN; COLLAGEN TYPE 4; CREATININE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBRONECTIN; FINGOLIMOD; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; CAPILLARY DENSITY; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DOWN REGULATION; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; GLOMERULUS CAPILLARY; IMMUNOHISTOCHEMISTRY; KIDNEY BLOOD VESSEL; KIDNEY FIBROSIS; KIDNEY PARENCHYMA; KIDNEY TUBULE CAPILLARY; MALE; MICROVASCULATURE; NEPHRECTOMY; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; RAT MODEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHAM PROCEDURE; SPRAGUE DAWLEY RAT; UREA NITROGEN BLOOD LEVEL; WESTERN BLOTTING;

ANIMALIA; RATTUS;

ANIMALS; COLLAGEN TYPE IV; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENDOTHELIAL CELLS; FIBRONECTINS; FIBROSIS; GENE EXPRESSION REGULATION; KIDNEY; KIDNEY GLOMERULUS; MALE; MICROVESSELS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PROPYLENE GLYCOLS; RATS; RENAL INSUFFICIENCY, CHRONIC; SPHINGOSINE; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84890569904     PISSN: 15672379     EISSN: 15672387     Source Type: Journal    
DOI: 10.1007/s10735-013-9521-8     Document Type: Article

References (45)

1. An WS, Kim HJ, Cho KH, Vaziri ND (2009) Omega-3 fatty acid supplementation attenuates oxidative stress, inflammation, and tubulointerstitial fibrosis intheremnant kidney. Am J Physiol Renal Physiol 297(4):895-903
2. Baylis C (2012) Nitric oxide synthase derangements and hypertension in kidney disease. Curr Opin Nephrol Hypertens 21:1-6
3. Brinkmann V, Cyster JG, Hla T (2004) FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 4:1019-1025
4. Desjardins F, Balligand JL (2006) Nitric oxide-dependent endothelial and cardiovascular disease. Acta Clin Belg 61:326-334
5. Diéguez G, García-Villalón AL (2011) Dilator and constrictor response of renal vasculature during acute renal hypotension in anesthetized goats. Role of nitric oxide. Vascul Pharmacol 54:107-111
6. Dudek SM, Camp SM, Chiang ET, Singleton PA, Usatyuk PV, Zhao Y, Natarajan V, Garcia JG (2007) Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor. Cell Signal 19(8):1754-1764
7. Egom EE, Mohamed TM, Mamas MA, Shi Y, Liu W, Chirico D, Stringer SE, Ke Y, Shaheen M, Wang T, Chacko S, Wang X, Solaro RJ, Fath-Ordoubadi F, Cartwright EJ, Lei M (2011) Activation of Pak1/Akt/eNOS signaling following sphingosine-1-phosphate release as part of a mechanism protecting cardiomyocytes against ischemic cell injury. Am J Physiol Heart Circ Physiol 301(4):H1487-H1495
8. English D, Welch Z, Kovala AT, Harvey K, Volpert OV et al (2000) Sphingosine 1-phosphate released from platelets during clotting accounts for the potent endothelial cell chemotactic activity of blood serum and provides a novel link between hemostasis and angiogenesis. FASEB J 14:2255-2265
9. Graler MH, Goetzl EJ (2004) The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J 18:551-553
10. Guerrot D, Dussaule JC, Kavvadas P, Boffa JJ, Chadjichristos CE, Chatziantoniou C (2012) Progression of renal fibrosis: the underestimated role of endothelial alterations. Fibrogenesis Tissue Repair 5(Suppl 1):S15
11. Hara A, Wada T, Furuichi K, Sakai N, Kawachi H, Shimizu F, Shibuya M, Matsushima K, Yokoyama H, Egashira K, Kaneko S (2006) Blockade of VEGF accelerates proteinuria, via decrease in nephrin expression in rat crescentic glomerulonephritis. Kidney Int 69(11):1986-1995
12. Huwiler A, Pfeilschifter J (2008) New players on the center stage: sphingosine 1-phosphate and its receptors as drug targets. Biochem Pharmacol 75:1893-1900
13. Igarashi J, Michel T (2008) S1P and eNOS regulation. Biochim Biophys Acta 1781:489-495
14. Igarashi J, Miyoshi M, Hashimoto T, Kubota Y, Kosa H (2007) Statins induce S1P1 receptors and enhance endothelial nitric oxide production in response to high-density lipoproteins. Br J Pharmacol 150:470-479
15. Inagami T, Naruse M, Hoover R (1995) Endothelium as an endocrine organ. Annu Rev Physiol 57:171-189
16. Ishii I, Fukushima N, Ye X, Chun J (2004) Lysophospholipid receptors: signaling and biology. Annu Rev Biochem 73:321-354
17. Ji L, Masuda S, Saito H, Inui K (2002) Down-regulation of rat organic cation transporter rOCT2 by 5/6 nephrectomy. Kidney Int 62:514-524
18. Kajimoto H, Kai H, Aoki H, Yasuoka S, Anegawa T, Aoki Y, Ueda S, Okuda S, Imaizumi T (2012) Inhibition of eNOS phosphorylation mediates endothelial dysfunction in renal failure: new effect of asymmetric dimethylarginine. Kidney Int 81:762-768
19. Kang DH, Kanellis J, Hugo C, Truong L, Anderson S, Kerjaschki D, Schreiner GF, Johnson RJ (2002) Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol 13:806-816
20. Kihara A, Igarashi Y (2008) Production and release of sphingosine 1-phosphate and the phosphorylated form of the immunomodulator FTY720. Biochim Biophys Acta 1781:496-502
21. Kiuchi M, Adachi K, Kohara T, Minoguchi M, Hanano T, Aoki Y, Mishina T, Arita M, Nakao N, Ohtsuki M, Hoshino Y, Teshima K, Chiba K, Sasaki S, Fujita T (2000) Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1, 3-diols and 2-aminoethanols. J Med Chem 43:2946-2961
22. Lee MJ, Van Brocklyn JR, Thangada S, Liu CH, Hand AR, Menzeleev R, Spiegel S, Hla T (1998) Sphingosine 1-phosphate as a ligand for the G-protein-coupled receptor Edg-1. Science 279:1552-1555
23. Lee MJ, Thangada S, Claffey KP, Ancellin N, Liu CH, Kluk M, Volpi M, Sha'afi RI, Hla T (1999) Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell 99:301-312
24. Masuda Y, Shimizu A, Mori T, Ishiwata T, Kitamura H, Ohashi R, Ishizaki M, Asano G, Sugisaki Y, Yamanaka N (2001) Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am J Pathol 159:599-608
25. Mathew B, Jacobson JR, Berdyshev E, Huang Y, Sun X, Zhao Y, Gerhold LM, Siegler J, Evenoski C, Wang T, Zhou T, Zaidi R, Moreno-Vinasco L, Bittman R, Chen CT, LaRiviere PJ, Sammani S, Lussier YA, Dudek SM, Natarajan V, Weichselbaum RR, Garcia JG (2011) Role of sphingolipids in murine radiation-induced lung injury: protection by sphingosine 1-phosphate analogs. FASEB J 25(10):3388-3400
26. 2+ mediates rac activation and adherens junction assembly in endothelial cells. J Biol Chem 280(17):17320-17328
27. Mount PF, Power DA (2006) Nitric oxide in the kidney: functions and regulation of synthesis. Acta Physiol 187:433-446
28. Nakayama T, Sato W, Kosugi T, Zhang L, Campbell-Thompson M, Yoshimura A, Croker BP, Johnson RJ, Nakagawa T (2009) Endothelial injury due to eNOS deficiency accelerates the progression of chronic renal disease in the mouse. Am J Physiol Renal Physiol 296(2):F317-F327
29. Nofer JR, van der Giet M, Tölle M, Wolinska I, von Wnuck Lipinski K, Baba HA, Tietge UJ, Gödecke A, Ishii I, Kleuser B, Schäfers M, Fobker M, Zidek W, Assmann G, Chun J, Levkau B (2004) HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 113:569-581
30. Okajima F (2002) Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti-atherogenic mediator? Biochim Biophys Acta 1582(1-3):132-137
31. Otunctemur A, Ozbek E, Cekmen M, Cakir SS, Dursun M, Polat EC, Somay A, Ozbay N (2013) Protective effect of montelukast which is cysteinyl-leukotriene receptor antagonist on gentamicin-induced nephrotoxicity and oxidative damage in rat kidney. Ren Fail 35(3):403-410
32. Penaranda C, Tang Q, Ruddle NH, Bluestone JA (2010) Prevention of diabetes by FTY720-mediated stabilization of peri-islet tertiary lymphoid organs. Diabetes 59:1461-1468
33. Sanchez T, Estrada-Hernandez T, Paik JH, Wu MT, Venkataraman K, Brinkmann V, Claffey K, Hla T (2003) Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J Biol Chem 278:47281-47290
34. Sarai K, Shikata K, Shikata Y, Omori K, Watanabe N, Sasaki M, Nishishita S, Wada J, Goda N, Kataoka N, Makino H (2009) Endothelial barrier protection by FTY720 under hyperglycemic condition: involvement of focal adhesion kinase, small GTPases, and adherens junction proteins. Am J Physiol Cell Physiol 297(4):C945-C954
35. Satoh M (2012) Endothelial dysfunction as an underlying pathophysiological condition of chronic kidney disease. Clin Exp Nephrol 16:518-521
36. Schaier M, Vorwalder S, Sommerer C, Dikow R, Hug F, Gross ML, Waldherr R, Zeier M (2009) Role of FTY720 on M1 and M2 macrophages, lymphocytes, and chemokines in 5/6 nephrectomizedrats. Am J Physiol Renal Physiol 297(3):769-780
37. Spyridopoulos I, Brogi E, Kearney M, Sullivan AB, Cetrulo C, Isner JM, Losordo DW (1997) Vascular endothelial growth factor inhibits endothelial cell apoptosis induced by tumor necrosis factor-alpha: balance between growth and death signals. J Mol Cell Cardiol 29:1321-1330
38. Strader CR, Pearce CJ, Oberlies NH (2011) Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite. J Nat Prod 74(4):900-907
39. Swan DJ, Kirby JA, Ali S (2010) Vascular biology: the role of sphingosine 1-phosphate in both the resting state and inflammation. J Cell Mol Med 14:2211-2222
40. 2+ mediates rac activation and adherens junction assembly in endothelial cells. J Biol Chem 280:17320-17328
41. Takuwa Y, Okamoto Y, Yoshioka K, Takuwa N (2008) Sphingosine-1-phosphate signaling and biological activities in the cardiovascular system. Biochim Biophys Acta 1781:483-488
42. Wang L, Dudek SM (2009) Regulation of vascular permeability by sphingosine 1-phosphate. Microvasc Res 77:39-45
43. Xin C, Ren S, Eberhardt W, Pfeilschifter J, Huwiler A (2006) The immunomodulator FTY720 and its phosphorylated derivative activate the Smad signalling cascade and upregulate connective tissue growth factor and collagen type IV expression in renal mesangial cells. Br J Pharmacol 147(2):164-174
44. Yin Z, Fan L, Wei L, Gao H, Zhang R, Tao L, Cao F, Wang H (2012) FTY720 protects cardiac microvessels of diabetes: a critical role of S1P1/3 in diabetic heart disease. PLoS One 7(8):e42900
45. Yu Y, Wang Y, Zhou LN, Zheng F (2011) ARB treatment prevents the decrease in endothelial progenitor cells and the loss of renal microvasculature in remnant kidney. Am J Nephrol 33(6):550-557